Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280161 · ClinicalTrials.gov registry record
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
A clinical trial of Malignant Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT02280161: Recruiting study of Malignant Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.
NCT02280161 is a study of Malignant Neoplasm that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 2,000 participants, above the 480-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (317% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02280161, a study of Malignant Neoplasm, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.
Primary Outcome
The prevalence of germ-line variants of interest will be compared to the baseline prevalence found using available large human genomic DNA collections. The primary statistical analysis will involve comparisons of genotypes between with (cases) and without (controls) the germ-line mutation. This analysis will include Pearson's chi-square analysis or Fisher's exact test and computation of odds ratios to assess the relationship of the genetic polymorphism and cancer risk.
Conditions Studied
Interventions
- OTHER cytology specimen collection procedure
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2027-09-16 |
What NCT02280161 shows while recruiting
NCT02280161 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 480-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (317% higher).
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which cytology specimen collection procedure is the first listed.
NCT02280161 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02280161 about?
NCT02280161 is a clinical study titled "Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer". This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited inc...
What is the current status of trial NCT02280161?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2014-09-16. Estimated completion is 2027-09-16.
What conditions does trial NCT02280161 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02280161?
The interventions under investigation include: cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02280161?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02280161 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02280161's enrollment target sits among peer trials
2,000 3rd of 59 higher than 57 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
Norris ORIEN Total Cancer Care
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI